{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T15:39:22Z","timestamp":1792424362051,"version":"4.5.0"},"reference-count":0,"publisher":"Esmon Publicidad, SA","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Investig Allergol Clin Immunol"],"abstract":"<jats:p>Asthma is a chronic inflammatory disease of the airways affecting more than 300 million people worldwide. It is estimated that between 3% and 10% have severe asthma. Depemokimab is the first ultra-long-acting anti\u2013IL-5 monoclonal antibody developed for type 2 respiratory disease, enabling administration every 26 weeks. It produces rapid and sustained reductions in blood eosinophil counts. This twice-yearly regimen markedly reduces injection frequency and may lessen treatment burden. In the replicate phase 3 SWIFT-1 and SWIFT-2 trials, depemokimab reduced the pooled annualized rate of clinically significant exacerbations by 54% and exacerbations requiring hospitalization or emergency department care by 72% compared with placebo in patients aged 12 years or older with severe eosinophilic asthma. In chronic rhinosinusitis with nasal polyps (CRSwNP), depemokimab was evaluated in the replicate phase 3 ANCHOR-1 and ANCHOR-2 trials. Both coprimary endpoints were met, and these studies provide evidence that twice-yearly depemokimab reduces the endoscopic nasal polyp score and improves nasal obstruction over 52 weeks in inadequately controlled CRSwNP. Depemokimab is approved for both severe asthma with type 2 inflammation and severe CRSwNP, making it a therapeutic option when both conditions coexist. Based on currently available evidence, depemokimab represents an additional option for patients with severe eosinophilic asthma in whom prevention of exacerbation is a major therapeutic goal. The twice-yearly dosing schedule may also be relevant when reducing treatment burden is a patient priority, although the effect of this reduction on adherence and persistence remains to be proved.<\/jats:p>","DOI":"10.18176\/jiaci.1229","type":"journal-article","created":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T14:43:52Z","timestamp":1792421032000},"source":"Crossref","is-referenced-by-count":0,"title":["Positioning of Depemokimab in Uncontrolled Severe Asthma"],"prefix":"10.18176","volume":"37","author":[{"given":"Juan Carlos","family":"Miralles-L\u00f3pez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ismael","family":"Garc\u00eda-Moguel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Habernau-Mena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel Jorge","family":"Rial-Prado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Montoro-Ferrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dar\u00edo","family":"Antol\u00edn-Am\u00e9rigo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7491","published-online":{"date-parts":[[2026,10,19]]},"container-title":["Journal of Investigational Allergology and Clinical Immunology"],"original-title":[],"deposited":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T14:43:52Z","timestamp":1792421032000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jiaci.org\/ahead-of-print\/positioning-of-depemokimab-in-uncontrolled-severe-asthma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,19]]},"references-count":0,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,10,19]]}},"URL":"https:\/\/doi.org\/10.18176\/jiaci.1229","relation":{},"ISSN":["1018-9068","1698-0808"],"issn-type":[{"value":"1018-9068","type":"print"},{"value":"1698-0808","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,19]]}}}